Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 22, 2026Investigative and Clinical UrologyOpen Access

Impact of repeated prostate-specific antigen testing on management patterns and personal healthcare spending for prostate cancer: A population-based study National Health Insurance data for 166,848 patients in South Korea from 2010 to 2020

View Full Paper
Ask AI
Bookmark
Share

Authors

YKYoung Hwii KoSKSang Won KimNSNak-Hoon Son

Discussion

Loading...

Member takes

Overview

A nationwide analysis reveals repeated PSA testing alters treatment choices and reduces healthcare costs in prostate cancer management.

Key Points

  • This study evaluates the impact of repeated prostate-specific antigen testing on treatment choices and healthcare expenditures for prostate cancer.
  • Analyzed a cohort of men newly diagnosed with prostate cancer from 2010 to 2020.
  • Classified patients based on PSA testing history (tested vs. non-tested).
  • Compared treatment patterns and medical expenses associated with different therapies.
  • 26.7% of men were PSA-tested while 42.2% were non-tested.
  • Increased localized therapy usage after repeated testing; surgery rates rose from 33.8% to 45.6% (p<0.001).
  • Men in the non-tested group faced higher costs for hormone therapy, but localized therapy costs remained similar.

Cite This Study

Ko et al. (2026) studied this question.

synapsesocial.com/papers/69e866c96e0dea528ddeb22dhttps://doi.org/10.4111/icu.20250537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prostate specific antigen retesting intervals and trends in England: population based cohort study2025
  2. 2PSA testing and receipt of curative treatment in elderly Japanese men with prostate cancer: a population-based study2026
  3. 3The economic impact of opportunistic PSA screening: a real-world cost analysis from China amid evolving policy landscape2026
  4. 4Out‐of‐pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men2024 · 4 citations
  5. 5Costing the national clinical guidelines for prostate cancer control and management in South Africa: Public sector perspective2026 · 2 citations